Author:
Fernandes Brígida Dias,D’Athayde Rodrigues Fernanda,Cardoso Cirilo Hérica Núbia,Borges Stéfani Sousa,Krug Bárbara Corrêa,Probst Livia Fernandes,Zimmermann Ivan
Subject
Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)
Reference26 articles.
1. Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review;Verhaart;Orphanet J Rare Dis,2017
2. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia;Wang;J Neurol,2022
3. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients;Malone;J Mark Access Health Policy,2019
4. Early cost-effectiveness of onasemnogene Abeparvovec-xioi (Zolgensma) and nusinersen (Spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios;Broekhoff;Value Health,2021
5. Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy;Naveed;J Pediatr Pharmacol Ther,2021